Bahat Özdoğan Elif, Özdemir Tuğba, Arslansoyu Çamlar Seçil, Imamoğlu Mustafa, Cobanoğlu Ümit, Sönmez Bircan, Tosun İlknur, Doğan Ismail
Department of Pediatrics, Division of Pediatric Nephrology, Faculty of Medicine, Karadeniz Technical University, 61080 Trabzon, Turkey.
Department of Pediatrics, Faculty of Medicine, Karadeniz Technical University, 61080 Trabzon, Turkey.
Biomed Res Int. 2014;2014:134940. doi: 10.1155/2014/134940. Epub 2014 Jul 3.
This study aimed to demonstrate if the addition of anti-inflammatory treatment to antibiotic therapy shows any superiority to the treatment with antibiotic only.
Forty-nine Wistar rats were divided into 7 groups. Pyelonephritis was performed by E. coli injection to upper pole of kidneys except control group. Group 2 was not treated. Ceftriaxone, ketoprofen, "ceftriaxone + ketoprofen," methylprednisolone, and "ceftriaxone + methylprednisolone" were given in the groups. The technetium-99m-dimercaptosuccinic acid scintigraphies were performed in 3rd day to detect pyelonephritis and 10th week to detect renal scarring. All kidneys were also histopathologically evaluated.
When 3rd day and 10th week scintigraphies were compared, initial 2.00 ± 0.30 point pyelonephritis score resulted in 0.71 ± 0.36 renal scar score in "ceftriaxone + ketoprofen" group (P = 0.039). Initial 2.00 ± 0.43 point pyelonephritis score resulted in 0.86 ± 0.26 renal scar score in "ceftriaxone + methylprednisolone" group (P = 0.041). Renal scar score was declined in "ceftriaxone + ketoprofen" group and "ceftriaxone + methylprednisolone" group compared with no-treatment group on 10th week of the study (P = 0.026, P = 0.044). On histopathological evaluation, it was seen that renal scar prevalence and expansion declined significantly in "ceftriaxone + ketoprofen and ceftriaxone + methylprednisolone" (P = 0.011, P = 0.023).
It was evidenced that ceftriaxone treatment in combination with ketoprofen or methylprednisolone declined scar formation in scintigraphic and histopathologic examinations of the kidneys.
本研究旨在证明在抗生素治疗中添加抗炎治疗是否比单纯使用抗生素治疗更具优势。
将49只Wistar大鼠分为7组。除对照组外,通过向肾脏上极注射大肠杆菌诱发肾盂肾炎。第2组未接受治疗。其他组分别给予头孢曲松、酮洛芬、“头孢曲松+酮洛芬”、甲泼尼龙以及“头孢曲松+甲泼尼龙”。在第3天进行锝-99m-二巯基丁二酸闪烁扫描以检测肾盂肾炎,在第10周进行检测以检测肾瘢痕形成。所有肾脏也进行了组织病理学评估。
比较第3天和第10周的闪烁扫描结果时,“头孢曲松+酮洛芬”组最初2.00±0.30分的肾盂肾炎评分导致0.71±0.36分的肾瘢痕评分(P=0.039)。“头孢曲松+甲泼尼龙”组最初2.00±0.43分的肾盂肾炎评分导致0.86±0.26分的肾瘢痕评分(P=0.041)。在研究的第10周,与未治疗组相比,“头孢曲松+酮洛芬”组和“头孢曲松+甲泼尼龙”组的肾瘢痕评分下降(P=0.026,P=0.044)。组织病理学评估显示,“头孢曲松+酮洛芬”组和“头孢曲松+甲泼尼龙”组的肾瘢痕发生率和扩展明显下降(P=0.011,P=0.023)。
有证据表明,在肾脏的闪烁扫描和组织病理学检查中,头孢曲松联合酮洛芬或甲泼尼龙治疗可减少瘢痕形成。